Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angus Lowry

Interventional Pain Medicine Amarillo, TX Medical Doctor

NPI 1073773727 CMS profile 185525

1901 Medi Park Dr Ste 2, Ste B200, Amarillo, TX 79106

Open in the dashboard

General payments

$20,961

757 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angus Lowry of Amarillo, TX is reported in the CMS Open Payments database as having received $20,961 across 757 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,529 25
2024 General $2,090 34
2023 General $2,535 118
2022 General $6,229 265
2021 General $4,188 135
2020 General $2,328 82
2019 General $2,062 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angus Lowry
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Angus Lowry were reported at $1,529. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Angus Lowry Interventional Pain Medicine median Middle half National median
2019 $2,062 $684 $216–$2,079 $163
2020 $2,328 $382 $122–$1,109 $114
2021 $4,188 $552 $167–$1,554 $132
2022 $6,229 $605 $187–$1,924 $149
2023 $2,535 $671 $195–$1,915 $160
2024 $2,090 $684 $206–$1,837 $164
2025 $1,529 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $19,861 730 payments
  2. Boston Scientific Corporation $329 5 payments
  3. Nevro Corp. $277 5 payments
  4. Vertiflex, Inc. $227 9 payments
  5. Stimwave Technologies Incorporated $70 1 payment
  6. Saluda Medical Americas, Inc. $56 1 payment
  7. AbbVie, Inc. $50 3 payments
  8. Medtronic, Inc. $50 1 payment
  9. ERMI Inc. $20 1 payment
  10. Relievant Medsystems, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,943 756 payments
  2. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $7,393 327 payments
  2. Proclaim Family of SCS IPGs $3,044 120 payments
  3. Octrode SCS Leads Neuromodulation $2,205 59 payments
  4. Proclaim IPG $1,831 69 payments
  5. OCTRODE $814 20 payments
  6. PROCLAIM Neuromodulation $590 10 payments
  7. PROCLAIM Neuromodulation $579 16 payments
  8. Octrode SCS Leads Cardiac Arrhythmias and Heart Failure $506 28 payments
  9. ETERNA $459 7 payments
  10. PROCLAIM Structural Heart $347 4 payments
  11. Other $3,103 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,179

Median for Interventional Pain Management: 1,220

Drug cost

$26,438

Median for Interventional Pain Management: $39,344

Branded share of claims

50.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 442 $12,476
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 19 $2,444
Gabapentin Generic 174 $2,135
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 82 $2,043
Pregabalin Generic 80 $1,781
Lidocaine Generic 17 $1,408
Morphine Sulfate Er Morphine Sulfate Brand 39 $978
Tramadol Hcl Generic 103 $750
Oxycodone Hcl Generic 50 $647
Cyclobenzaprine Hcl Generic 40 $458

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$99,478

Medicare's payments for the services billed

Medicare patients

311

Average age 73

Services billed

1,678

179 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 35%
Diabetes 34%
Chronic kidney disease 23%
COPD 22%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

757 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record